JP2012529523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529523A5 JP2012529523A5 JP2012515079A JP2012515079A JP2012529523A5 JP 2012529523 A5 JP2012529523 A5 JP 2012529523A5 JP 2012515079 A JP2012515079 A JP 2012515079A JP 2012515079 A JP2012515079 A JP 2012515079A JP 2012529523 A5 JP2012529523 A5 JP 2012529523A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- liver
- ornithine
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 14
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 8
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 7
- 229960003104 ornithine Drugs 0.000 claims 7
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 6
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 6
- 229940049953 phenylacetate Drugs 0.000 claims 6
- 229950009215 phenylbutanoic acid Drugs 0.000 claims 6
- 210000004185 liver Anatomy 0.000 claims 5
- 208000019423 liver disease Diseases 0.000 claims 5
- 208000007232 portal hypertension Diseases 0.000 claims 5
- 208000007788 Acute Liver Failure Diseases 0.000 claims 4
- 206010000804 Acute hepatic failure Diseases 0.000 claims 4
- 231100000836 acute liver failure Toxicity 0.000 claims 4
- 230000003908 liver function Effects 0.000 claims 4
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 230000000740 bleeding effect Effects 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 claims 1
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 206010065441 Venous haemorrhage Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 229960003424 phenylacetic acid Drugs 0.000 claims 1
- 239000003279 phenylacetic acid Substances 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18515809P | 2009-06-08 | 2009-06-08 | |
| US61/185,158 | 2009-06-08 | ||
| US24074809P | 2009-09-09 | 2009-09-09 | |
| US61/240,748 | 2009-09-09 | ||
| US29637710P | 2010-01-19 | 2010-01-19 | |
| US61/296,377 | 2010-01-19 | ||
| PCT/US2010/037838 WO2010144498A2 (en) | 2009-06-08 | 2010-06-08 | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015098205A Division JP6250588B2 (ja) | 2009-06-08 | 2015-05-13 | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529523A JP2012529523A (ja) | 2012-11-22 |
| JP2012529523A5 true JP2012529523A5 (cg-RX-API-DMAC7.html) | 2013-07-18 |
| JP5749255B2 JP5749255B2 (ja) | 2015-07-15 |
Family
ID=43309444
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515079A Active JP5749255B2 (ja) | 2009-06-08 | 2010-06-08 | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
| JP2015098205A Active JP6250588B2 (ja) | 2009-06-08 | 2015-05-13 | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
| JP2016238546A Active JP6527497B2 (ja) | 2009-06-08 | 2016-12-08 | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015098205A Active JP6250588B2 (ja) | 2009-06-08 | 2015-05-13 | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
| JP2016238546A Active JP6527497B2 (ja) | 2009-06-08 | 2016-12-08 | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20120157526A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2440200B8 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5749255B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101715008B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN102625699B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010258888B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1012956A8 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2997484C (cg-RX-API-DMAC7.html) |
| DK (2) | DK2440200T3 (cg-RX-API-DMAC7.html) |
| EA (2) | EA025735B1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2517340T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL216811A (cg-RX-API-DMAC7.html) |
| MX (3) | MX375116B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ596916A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2440200T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG176675A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010144498A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201108988B (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2153870E (pt) | 2004-11-26 | 2014-03-12 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| NZ708458A (en) | 2009-04-03 | 2017-02-24 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| EA025735B1 (ru) | 2009-06-08 | 2017-01-30 | ЮСиЭл БИЗНЕС ПиЭлСи | Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата |
| ES2720148T3 (es) | 2010-10-06 | 2019-07-18 | Ocera Therapeutics Inc | Métodos de fabricación de fenilacetato de L-ornitina |
| CN102993037B (zh) * | 2012-11-20 | 2015-03-04 | 南京工业大学 | 一种l-鸟氨酸苯乙酸盐的制备方法 |
| RS58375B1 (sr) | 2014-01-29 | 2019-03-29 | Umecrine Cognition Ab | Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije |
| CA2965325A1 (en) | 2014-10-24 | 2016-04-28 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| NZ732632A (en) * | 2014-11-24 | 2021-07-30 | Ucl Business Ltd | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ａｂ公司 | 新穎化合物 |
| EP3285756B1 (en) * | 2015-04-20 | 2023-02-22 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| JP2017014206A (ja) * | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
| US10835506B2 (en) | 2015-08-18 | 2020-11-17 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| JP6989495B2 (ja) * | 2015-09-25 | 2022-01-05 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防 |
| US11219611B2 (en) * | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| CA3004331A1 (en) * | 2015-11-13 | 2017-05-18 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| CN106109429A (zh) * | 2016-07-26 | 2016-11-16 | 北京百奥药业有限责任公司 | 一种苯丁酸钠片剂及其制备方法 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| US11160826B1 (en) | 2017-03-03 | 2021-11-02 | United States Government As Represented By The Department Of Veterans Affairs | Cholesterol lowering drugs for the treatment of hepatic encephalopathy |
| KR20200024145A (ko) | 2017-05-11 | 2020-03-06 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐아세테이트의 제조방법 |
| CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
| WO2019173148A1 (en) * | 2018-03-05 | 2019-09-12 | The United States Government As Represented By The United States Department Of Veterans Affairs | Cholesterol lowering drugs for the treatment of hepatic encephalopathy |
| AR115585A1 (es) | 2018-06-20 | 2021-02-03 | Axcella Health Inc | Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo |
| JP2022533569A (ja) | 2019-05-09 | 2022-07-25 | オセラ セラピューティクス， インコーポレイテッド | 肝性脳症を評価および処置する方法 |
| KR20220011697A (ko) | 2019-05-22 | 2022-01-28 | 바이오비에 아이앤씨. | 테를리프레신 제형 |
| KR102237526B1 (ko) * | 2019-11-07 | 2021-04-07 | 한국식품연구원 | 오르니틴 생성능이 우수한 락토바실러스 브레비스 wikim47를 이용한 마늘 발효 조성물 |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (cg-RX-API-DMAC7.html) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| FR2113774A1 (en) | 1970-11-13 | 1972-06-30 | Roques Ets | Prepn of l-ornithine salts with org acids - using silver oxides |
| US4100161A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US4857555A (en) | 1985-09-12 | 1989-08-15 | Brigham & Women's Hospital | Method of treating catabolic dysfunction |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US5139981A (en) | 1987-06-24 | 1992-08-18 | Union Carbide Chemicals & Plastics Technology Corporation | Process for preparing silver(I)-exchanged resins |
| JP2522034B2 (ja) | 1988-12-27 | 1996-08-07 | 味の素株式会社 | α−ケト酸・アミノ酸塩化合物及びその製造方法 |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| DE4020980C1 (cg-RX-API-DMAC7.html) | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| JP3127484B2 (ja) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US5856481A (en) | 1994-07-28 | 1999-01-05 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| IL139728A (en) | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
| FI972744L (fi) * | 1995-02-23 | 1997-08-22 | Novartis Nutrition Ag | Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa |
| AU2251897A (en) | 1996-02-13 | 1997-09-02 | Trustees Of The University Of Pennsylvania, The | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| EP1179347A4 (en) | 1999-05-21 | 2002-06-26 | Takeda Chemical Industries Ltd | CONTROL SUBSTANCES FOR LIVER FUNCTION |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| CN1304723A (zh) | 2001-01-16 | 2001-07-25 | 中山大学 | 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物 |
| DE60233558D1 (de) | 2001-03-15 | 2009-10-15 | Takashi Abe | Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| CN1383815A (zh) | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| AU2003261825A1 (en) | 2002-08-30 | 2004-03-19 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
| US20050059150A1 (en) | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (es) | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| KR20110124317A (ko) | 2004-05-06 | 2011-11-16 | 오스테올로지스 에이에스 | 금속 유기 염의 제조를 위한 고 수율 및 고속 합성 방법 |
| WO2006059237A1 (en) | 2004-08-30 | 2006-06-08 | Lunamed, Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| PT2153870E (pt) * | 2004-11-26 | 2014-03-12 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| WO2007077995A1 (ja) | 2006-01-05 | 2007-07-12 | Kyowa Hakko Kogyo Co., Ltd. | 筋肉増量剤 |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| CA2727088A1 (en) | 2008-06-04 | 2009-12-10 | Phenolics, Llc | Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same |
| AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| NZ708458A (en) | 2009-04-03 | 2017-02-24 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| CA2763894A1 (en) | 2009-06-02 | 2011-01-13 | Salix Pharmaceuticals, Ltd. | Use of rifaximin to maintain remission of hepatic encephalopathy |
| EA025735B1 (ru) | 2009-06-08 | 2017-01-30 | ЮСиЭл БИЗНЕС ПиЭлСи | Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата |
| AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| JP2011236160A (ja) | 2010-05-11 | 2011-11-24 | Shinshu Univ | 非アルコール性肝疾患治療薬 |
| ES2720148T3 (es) | 2010-10-06 | 2019-07-18 | Ocera Therapeutics Inc | Métodos de fabricación de fenilacetato de L-ornitina |
| ES2654774T3 (es) | 2012-11-21 | 2018-02-15 | Horizon Therapeutics, Llc | Métodos para administrar y evaluar fármacos de recuperación de nitrógeno para el tratamiento de encefalopatía hepática |
| CN103705490B (zh) | 2013-10-31 | 2016-08-17 | 蚌埠丰原医药科技发展有限公司 | 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺 |
| NZ732632A (en) | 2014-11-24 | 2021-07-30 | Ucl Business Ltd | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| EP3285756B1 (en) | 2015-04-20 | 2023-02-22 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| US10835506B2 (en) | 2015-08-18 | 2020-11-17 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| JP6989495B2 (ja) | 2015-09-25 | 2022-01-05 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防 |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
-
2010
- 2010-06-08 EA EA201171396A patent/EA025735B1/ru not_active IP Right Cessation
- 2010-06-08 SG SG2011089828A patent/SG176675A1/en unknown
- 2010-06-08 WO PCT/US2010/037838 patent/WO2010144498A2/en not_active Ceased
- 2010-06-08 CN CN201080035200.0A patent/CN102625699B/zh active Active
- 2010-06-08 EP EP10786721.0A patent/EP2440200B8/en active Active
- 2010-06-08 US US13/375,463 patent/US20120157526A1/en not_active Abandoned
- 2010-06-08 DK DK10786721.0T patent/DK2440200T3/en active
- 2010-06-08 EP EP19158338.4A patent/EP3517110A1/en not_active Withdrawn
- 2010-06-08 CA CA2997484A patent/CA2997484C/en active Active
- 2010-06-08 EA EA201691430A patent/EA201691430A1/ru unknown
- 2010-06-08 KR KR1020127000293A patent/KR101715008B1/ko active Active
- 2010-06-08 BR BRPI1012956A patent/BRPI1012956A8/pt not_active Application Discontinuation
- 2010-06-08 JP JP2012515079A patent/JP5749255B2/ja active Active
- 2010-06-08 DK DK14175859.9T patent/DK2799067T3/da active
- 2010-06-08 ES ES10786721.0T patent/ES2517340T3/es active Active
- 2010-06-08 NZ NZ596916A patent/NZ596916A/xx unknown
- 2010-06-08 CA CA2764587A patent/CA2764587C/en active Active
- 2010-06-08 AU AU2010258888A patent/AU2010258888B2/en active Active
- 2010-06-08 MX MX2015012475A patent/MX375116B/es unknown
- 2010-06-08 NZ NZ61509110A patent/NZ615091A/en unknown
- 2010-06-08 EP EP14175859.9A patent/EP2799067B1/en active Active
- 2010-06-08 ES ES14175859T patent/ES2728948T3/es active Active
- 2010-06-08 PL PL10786721T patent/PL2440200T3/pl unknown
- 2010-06-08 CN CN201410350083.7A patent/CN104434894A/zh active Pending
- 2010-06-08 KR KR1020177005930A patent/KR20170026672A/ko not_active Ceased
- 2010-06-08 MX MX2011013129A patent/MX2011013129A/es active IP Right Grant
-
2011
- 2011-12-07 ZA ZA2011/08988A patent/ZA201108988B/en unknown
- 2011-12-07 IL IL216811A patent/IL216811A/en active IP Right Grant
- 2011-12-07 MX MX2020009703A patent/MX2020009703A/es unknown
-
2015
- 2015-05-13 JP JP2015098205A patent/JP6250588B2/ja active Active
-
2016
- 2016-11-02 IL IL248696A patent/IL248696B/en active IP Right Grant
- 2016-12-08 JP JP2016238546A patent/JP6527497B2/ja active Active
-
2017
- 2017-11-20 US US15/817,847 patent/US11266620B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012529523A5 (cg-RX-API-DMAC7.html) | ||
| Kalantar-Zadeh et al. | Nutritional and anti-inflammatory interventions in chronic heart failure | |
| JP2013040176A5 (cg-RX-API-DMAC7.html) | ||
| JP2007262090A5 (cg-RX-API-DMAC7.html) | ||
| JP2012527447A5 (cg-RX-API-DMAC7.html) | ||
| EA201170018A1 (ru) | Разагилин для изменения течения болезни паркинсона | |
| JP2015007090A5 (cg-RX-API-DMAC7.html) | ||
| EA201792541A3 (ru) | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени | |
| JP2011511006A5 (ja) | 肺病態に対する医薬組成物 | |
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| HK1251149A1 (zh) | L-鸟氨酸苯乙酸盐制剂 | |
| JP2011251155A5 (cg-RX-API-DMAC7.html) | ||
| WO2011106106A3 (en) | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae | |
| JP2013527189A5 (cg-RX-API-DMAC7.html) | ||
| JP2018523683A5 (cg-RX-API-DMAC7.html) | ||
| MX352647B (es) | Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato. | |
| JP2017515854A5 (cg-RX-API-DMAC7.html) | ||
| RU2013155509A (ru) | Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности | |
| JP2016519106A5 (cg-RX-API-DMAC7.html) | ||
| JP2013530208A5 (cg-RX-API-DMAC7.html) | ||
| MX2012001107A (es) | Derivado de amida. | |
| JP2017508455A5 (cg-RX-API-DMAC7.html) | ||
| JP2011012060A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0506485A (pt) | método para reduzir o tempo de recuperação de um mamìfero submetido a uma anestesia geral, método para aumentar a recuperação de sepsia e uma composição adequada para administração intravenosa | |
| RU2006123285A (ru) | Способ выявления группы риска по артериальной гипертензии у подростков с синдромом вегетативной дистонии |